EP Patent

EP4119123A1 — Orally disintegrating film composition comprising buprenorphine

Assigned to GL Pharma GmbH · Expires 2023-01-18 · 3y expired

What this patent protects

Disclosed is an orally disintegrating film composition comprising Buprenorphine as active ingredient and a polymeric matrix, which is comprising of a combination of at least two water-soluble film forming polymers to form a polymeric matrix and wherein Buprenorphine is uniformly …

USPTO Abstract

Disclosed is an orally disintegrating film composition comprising Buprenorphine as active ingredient and a polymeric matrix, which is comprising of a combination of at least two water-soluble film forming polymers to form a polymeric matrix and wherein Buprenorphine is uniformly dispersed as particles within the polymeric matrix.

Drugs covered by this patent

Patent Metadata

Patent number
EP4119123A1
Jurisdiction
EP
Classification
—
Expires
2023-01-18
Drug substance claim
No
Drug product claim
No
Assignee
GL Pharma GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.